| Range: | 168.25-368.29 | Vol Avg: | 380834 | Last Div: | 0 | Changes: | 18.21 |
| Beta: | -0.47 | Cap: | 7.58B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Tue Feb 06 2007 | Empoloyees: | 376 | ||
| CUSIP: | 558868105 | CIK: | 0001157601 | ISIN: | US5588681057 | Country: | US |
| CEO: | Mr. William J. Sibold | Website: | https://www.madrigalpharma.com | ||||
MDGL 348.99 Stock Price Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Stock Details
Positive 0.20
1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More
There's a bright future ahead for this company....
fool.com·Sun Nov 10 2024
Positive 0.20
Here's Why Madrigal (MDGL) is a Great Momentum Stock to Buy
Does Madrigal (MDGL) have what it takes to be a top stock pick for momentum investors? Let...
zacks.com·Thu Nov 07 2024
Positive 0.21
Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion
Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval...
seekingalpha.com·Sun Nov 03 2024
Negative -0.27
Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates
Madrigal (MDGL) came out with a quarterly loss of $4.92 per share versus the Zacks Consens...
zacks.com·Thu Oct 31 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow